title: [Relationship between bcl-X(L) expression and sensitivity to chemotherapy in acute myeloid leukemic cells].
abstract: OBJECTIVE
  To investigate the characteristics and regulation of apoptosis in acute myeloid leukemic cells.
  
  
  METHODS
  Flow cytometry, DNA electrophoresis and Northern blot were used to analyze the expression of bcl-X(L) before and after Vp16 treatment, and the relationships between bcl-X(L) expression and apoptotic sensitivity, clinical features and prognosis were also analyzed.
  
  
  RESULTS
  Most of the leukemic cells from AML patients overexpressed bcl-X(L) mRNA. The expression of bcl-X(L) was still maintained high level after Vp16 treatment in patients with pretreatment overexpression. These patients were resistant to apoptosis, poor responsed to chemotherapy and associated with adverse prognostic features, such as high WBC counts, local leukemic infiltrations. Bone marrow cells from long-term remission AML patients and normal controls also showed bcl-X(L) downregulation after in vitro Vp16 treatment, but the apoptotic rates were lower than that in nonremissive AML.
  
  
  CONCLUSIONS
  Overexpression of bcl-XL played an important role in leukemogenesis and drug resistance. Downregulation of bcl-X(L) was necessary but not sufficient to initiate apoptosis.
authors.affiliation: Institute of Hematology, Union Hospital, Tongji Medical University, Wuhan 430022.
authors.forename: J
authors.initials: J
authors.lastname: Zhou
authors.forename: Y
authors.initials: Y
authors.lastname: Chen
authors.forename: C
authors.initials: C
authors.lastname: Li
authors.forename: B
authors.initials: B
authors.lastname: Wang
authors.forename: B
authors.initials: B
authors.lastname: Wang
authors.forename: Z
authors.initials: Z
authors.lastname: Qiao
authors.forename: M
authors.initials: M
authors.lastname: Zhou
authors.forename: H W
authors.initials: HW
authors.lastname: Findley
authors.forename: B
authors.initials: B
authors.lastname: Wang
mesh_terms: D000293:Adolescent; D000328:Adult; D017209:Apoptosis / Q000187:drug effects; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D005047:Etoposide / Q000494:pharmacology / Q000627:therapeutic use; D015972:Gene Expression Regulation, Neoplastic; D018922:HL-60 Cells; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D008875:Middle Aged; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D014158:Transcription, Genetic / Q000187:drug effects; D055815:Young Adult; D051020:bcl-X Protein / Q000235:genetics*
chemical_list: D012333:RNA, Messenger; D051020:bcl-X Protein; D005047:Etoposide